I-Mab Biopharma Stock: Caution Warranted After Huge Surge (NASDAQ:IMAB)

Core Insights - I-Mab's shares have experienced significant growth in 2025 due to increasing enthusiasm for its lead asset, givastomig [1] - The combination of givastomig with chemotherapy and Opdivo achieved an overall response rate (ORR) of 83%, with 10 out of 12 patients responding positively [1] Company Performance - The strong performance of I-Mab's stock is attributed to the promising results of its clinical trials involving givastomig [1] - The investment community is closely monitoring I-Mab's developments, particularly in the immuno-oncology sector [1]